The Trump administration on Monday asked a judge to toss out a lawsuit from three GOP-led states seeking to cut off telehealth access to abortion medication mifepristone.

Dr. Marty Makary, President Trump's pick to run the Food and Drug Administration, faced questions from the Senate HELP Committee on the abortion pill, vaccines, FDA firings and chemicals in food.

As the number of abortions nationwide grows, pregnant people in states with restrictions and bans are getting pills from out-of-state providers. Some say these providers are breaking the law.

The Supreme Court will be issuing major rulings in the next month. Normally by this point in the term there are between four and six really big cases left. This year, there are over a dozen.

The Comstock Act is the latest front in the fight over reproductive rights. Here's what you need to know about the 1873 law and the consequences if it's enforced the way some conservatives would like.

At issue in the case is more than abortion rights. It's the entire structure of the FDA's regulatory power to approve drugs and continually evaluate their safety.

The case could affect not just abortion access but oversight of the drug industry and the authority of federal agencies. The court hears arguments Tuesday.

Anti-abortion groups, attorneys general from 25 states and more than 140 members of Congress have signed on to dozens of briefs to the U.S. Supreme Court during the past two weeks, encouraging the justices to revert use and prescribing of the medication abortion pill mifepristone to what was in place prior to 2016.

CVS will start filling prescriptions for mifepristone in Massachusetts and Rhode Island. Walgreens will start in New York, Pennsylvania, Massachusetts, California and Illinois.

The study looks at 6,000 patients who got abortion pills after an online appointment. It found that 99.7% of those abortions were not followed by any serious adverse events.

A research paper that raises questions about the safety of abortion has been retracted. The research is cited in a federal judge's ruling about the abortion pill mifepristone.

They're pioneering a new model of care that will allow for one-stop, same-day access to mifepristone — no appointment necessary.

As the first full year since Roe v. Wade was overturned closes, the abortion landscape in the U.S. has changed legally, politically and medically.

The court's action sets up a collision between the Food and Drug Administration's 23-year study and supervision of mifepristone, and the circumstances under which it can be prescribed.

A federal appeals court would restrict the use of mifepristone, a pill used in medication abortions. But previous action by the Supreme Court means the status quo holds for now.